Parallel Advisors’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-62
| Closed | -$975 | – | 3453 |
|
|
2024
Q1 | $975 | Hold |
62
| – | – | ﹤0.01% | 2937 |
|
|
2023
Q4 | $1K | Sell |
62
-186
| -75% | -$2.37K | ﹤0.01% | 2931 |
|
|
2023
Q3 | $3.15K | Hold |
248
| – | – | ﹤0.01% | 2670 |
|
|
2023
Q2 | $3.49K | Hold |
248
| – | – | ﹤0.01% | 2562 |
|
|
2023
Q1 | $3.83K | Hold |
248
| – | – | ﹤0.01% | 2507 |
|
|
2022
Q4 | $4.07K | Sell |
248
-7
| -3% | -$114 | ﹤0.01% | 2426 |
|
|
2022
Q3 | $5K | Buy |
255
+7
| +3% | +$110 | ﹤0.01% | 2342 |
|
|
2022
Q2 | $3K | Buy |
248
+215
| +652% | +$2.37K | ﹤0.01% | 2510 |
|
|
2022
Q1 | $0 | Sell |
33
-641
| -95% | -$5.45K | ﹤0.01% | 3349 |
|
|
2021
Q4 | $7K | Buy |
674
+587
| +675% | +$11K | ﹤0.01% | 2287 |
|
|
2021
Q3 | $3K | Buy |
87
+77
| +770% | +$2.46K | ﹤0.01% | 2615 |
|
|
2021
Q2 | $0 | Sell |
10
-25
| -71% | -$968 | ﹤0.01% | 3100 |
|
|
2021
Q1 | $2K | Buy |
35
+25
| +250% | +$1.16K | ﹤0.01% | 2543 |
|
|
2020
Q4 | $1K | Sell |
10
-30
| -75% | -$1.78K | ﹤0.01% | 2517 |
|
|
2020
Q3 | $2K | Sell |
40
-28
| -41% | -$1.37K | ﹤0.01% | 2371 |
|
|
2020
Q2 | $4K | Buy |
+68
| New | +$3.64K | ﹤0.01% | 2048 |
|
Other funds holding DCPH
Parallel Advisors's DCPH Position: Q2 2024 in Review
Parallel Advisors sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 62 shares — an estimated $975 sold.
Parallel Advisors first reported a position in DCPH in Q2 2020 and held it in 16 quarters. The position peaked at $7K in Q4 2021. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- Parallel Advisors reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Parallel Advisors sold 62 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $975.
- Parallel Advisors first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 16 quarters.
- Parallel Advisors's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $7K in Q4 2021.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Parallel Advisors's 13F filing for Q2 2024, filed 8 Aug 2024.